19 completed, 7 unknown, 6 recruiting, 4 not yet recruiting. 12 Not applicable, 6 Phase 3, 6 Phase 4, 5 Phase 2, 2 Phase 1.
Follow Acute Coronary Syndrome (ACS): new trials by email Literature Review of Acute Coronary Syndrome (ACS) trials Research Report on Acute Coronary Syndrome (ACS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL Pelacarsen, Placebo - Acute Coronary Syndrome (ACS) | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2026-09-01 | 2026-10-14 | |
| Self-Management Support for Acute Coronary Syndrome Patients After Hospital Discharge COM-B and HAPA-based Self-management Support Program, Routine Health Education - Acute Coronary Syndrome (ACS) | Not applicable | Not yet recruiting | Nanfang Hospital, Southern Medical University | 80 | 2026-09-01 | 2026-09-04 |
| TeleheartCR vs. Clinic-Based Cardiac Rehabilitation After Acute Coronary Syndrome Telehealth-enhanced Hybrid CR, Traditional Cardiac Rehabilitation - Acute Coronary Syndrome (ACS), Myocardial Infarction | Not applicable | Recruiting | Columbia University | 250 | 2026-05-19 | 2026-06-03 |
| Leave Nothing Behind Study Which Compares DCB With Bail Out BRS Versus BRS Strategy Alone Angioplasty with DCB (bail-out BRS), Angioplasty with BRS - Drug Coated Balloon, Bioresorbable Scaffold | Not applicable | Recruiting | Ceric Sàrl | 2256 | 2026-04-24 | 2026-04-30 |
| Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk IVUS-guided BioFreedomTM Drug-Coated Stent Implantation + 1-Month DAPT Followed by 11-Month P2Y12 Inhibitor Monotherapy, Angiography-guided Conventional Drug-Eluting Stent Implantation + 12-Month Dual Antiplatelet Therapy (Aspirin + P2Y12 Inhibitor) - Acute Coronary Syndrome (ACS), High Bleeding Risk(HBR) | Not applicable | Not yet recruiting | Shenyang Northern Hospital | 468 | 2026-03-01 | 2026-01-29 |
| Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation on Alleviating Major Depressive Disorder in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention:A Prospective, Double-Blind,Randomized Controlled Study Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Intervention, sham Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) Control - Depressive Disorder (Per DSM-V Criteria, Mild-to-moderate), Acute Coronary Syndrome (ACS) | Not applicable | Recruiting | Jing Han | 120 | 2026-01-06 | 2026-06-16 |
| Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy Acute Coronary Syndrome (ACS), High Bleeding Risk (HBR) | Not yet recruiting | Shenyang Northern Hospital | 3500 | 2025-12-30 | 2026-01-21 | |
| Ticino Artificial InTelligence integrAtioN for Occlusion Myocardial Infarction AI-assisted ECG interpretation (PMcardio) - Myocardial Infarction (MI), Acute Coronary Syndrome (ACS) | Not applicable | Recruiting | Cardiocentro Ticino | 500 | 2025-08-23 | 2026-05-05 |
| Orbital Atherectomy vs Intravascular Lithotripsy for the Treatment of Calcified Coronary Nodules (ORBIT-SHOCK). Orbital atherectomy, Intravascular lithotripsy, Optical Coherence Tomography (OCT) - Coronary Arterial Disease (CAD), Coronary Calcification | Not applicable | Recruiting | Spanish Society of Cardiology | 50 | 2025-06-12 | 2026-04-30 |
| Effect of Olive Leaf Extracts on Endothelial Dysfunction in Patients With Acute Coronary Syndrome Atherolive 500mg/day, Atherolive 1000/day, Placbo_Atherolive - Acute Coronary Syndrome (ACS), Reactive Hyperemia | Phase 2 / Phase 3 | Not yet recruiting | University of Monastir | 300 | 2024-12-01 | 2024-12-09 |
| RESTORE Imaging: an OCT-IVUS Imaging Substudy of RESTORE Trial Drug-coated balloon, Guideline-directed medical treatment - Acute Coronary Syndrome (ACS) | Not applicable | Unknown | Harbin Medical University | 180 | 2024-06-25 | 2024-07-15 |
| Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque (RESTORE Trial) Drug-coated balloon, Guideline-directed medical treatment - Acute Coronary Syndrome (ACS) | Not applicable | Recruiting | Harbin Medical University | 1860 | 2024-04-16 | 2024-05-22 |
| OPTImal Management of Antithrombotic Agents: OPTIMA-5 Switch ticagrelor to clopidogrel - Acute Coronary Syndrome (ACS) | Phase 4 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 80 | 2020-06-22 | 2020-08-25 |
| Implementing Precision Medicine Approaches to Guide Anti-platelet Selection CYP2C19 genotyping - Acute Coronary Syndrome (ACS), STEMI - ST Elevation Myocardial Infarction (MI) | Phase 4 | Unknown | University of Southern California | 200 | 2020-03-13 | 2021-09-28 |
| Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI) Prasugrel - Acute Coronary Syndrome (ACS) | Phase 4 | Completed | Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company | 204 | 2018-10-16 | 2021-11-12 |
| VITROS Immunodiagnostic Products hs Troponin I Acute Coronary Syndrome (ACS), Myocardial Infarction | Unknown | Ortho-Clinical Diagnostics, Inc. | 1630 | 2018-06-07 | 2020-09-16 | |
| Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4) Triple antithrombotic therapy, Dual antithrombotc therapy-1, Dual antithrombotc therapy-2 - Acute Coronary Syndrome (ACS), Non-valvular Atrial Fibrillation (NVAF) | Phase 4 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 3746 | 2018-02-03 | 2023-04-24 |
| The Effect of IV Cangrelor and Oral Ticagrelor Study Cangrelor, Ticagrelor - Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR) | Phase 4 | Completed | The Royal Wolverhampton Hospitals NHS Trust | 100 | 2016-07-21 | 2025-05-02 |
| Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients Acute Coronary Syndrome (ACS) | Completed | AstraZeneca | 1066 | 2015-05-28 | 2018-03-14 | |
| EndoTic - Endothelium and Ticagrelor Ticagrelor vs Clopidogrel - Acute Coronary Syndrome (ACS) | Not applicable | Completed | Fundación Investigación Sanitaria en León | 109 | 2015-03-01 | 2016-11-23 |
Showing 20 of 39. Sign in to see all of them.
Acute Coronary Syndrome (39) · Myocardial Infarction (8) · ST Elevation Myocardial Infarction (6) · Coronary Artery Disease (5) · Angina, Unstable (4) · Non-ST Elevated Myocardial Infarction (3) · Atherosclerosis (2) · Depression (2) · Inflammation (2) · Atrial Fibrillation (1) · Autonomic Nervous System Diseases (1) · Behavior (1) · Cardiovascular Diseases (1) · Cerebrovascular Disorders (1) · Coronary Disease (1)
Myocardial Ischemia (39) · Vascular Diseases (39) · Cardiovascular Diseases (38) · Heart Diseases (38) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Infarction (11) · Ischemia (11) · Necrosis (11) · Arterial Occlusive Diseases (6) · Arteriosclerosis (6) · Coronary Disease (5) · Neurologic Manifestations (5) · Signs and Symptoms (5) · Angina Pectoris (4)
Prasugrel Hydrochloride (3) · Ticagrelor (3) · cangrelor (3) · Clopidogrel (2) · Oxygen (2) · Angioplasty (1) · Atorvastatin (1) · Dual Anti-Platelet Therapy (1) · Heparin (1) · Heparin, Low-Molecular-Weight (1) · Methods (1) · Percutaneous Coronary Intervention (1) · Sertraline (1) · Simvastatin (1) · Tomography, Optical Coherence (1)
Harbin Medical University (2) · Karolinska Institutet (2) · Shenyang Northern Hospital (2) · The First Affiliated Hospital with Nanjing Medical University (2) · The Medicines Company (2) · Abbott RDx Cardiometabolic (1) · AstraZeneca (1) · Bristol-Myers Squibb (1) · CES University (1) · Canadian Institutes of Health Research (CIHR) (1) · Cardiocentro Ticino (1) · Ceric Sàrl (1) · Columbia University (1) · Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company (1) · Deutsches Herzzentrum Muenchen (1)
United States (10) · China (9) · Germany (4) · Sweden (4) · Canada (3) · France (3) · Spain (3) · United Kingdom (3) · Austria (2) · Belgium (2) · Italy (2) · Switzerland (2) · Colombia (1) · Denmark (1) · Estonia (1)
Chunjian Li, Dr, PhD (2) · Adnan Kastrati, MD (1) · Andrea T. Duran, PhD (1) · Andrew S Worster, MD, MSc, CCFP(EM), FCFP (1) · Bo Yu (1) · Bo Yu, PhD (1) · Changsheng Ma (1) · David Erlinge, MD, PhD (1) · Deepak L. Bhatt, MD (1) · Devereaux P.J., MD, PhD (1) · Eric Topol, MD (1) · Frank Peacock, MD (1)
PMID 19470889, PMID 19915222, PMID 21315207, PMID 21503856, PMID 21511219, PMID 21670242, PMID 22253393, PMID 22305835, PMID 23460596, PMID 24371012, PMID 24576515, PMID 24852804, PMID 24929350, PMID 26585621, PMID 27902833, PMID 28062631, PMID 28183511, PMID 28279316, PMID 28342713, PMID 28382371, PMID 28668141, PMID 28988157, PMID 29169258, PMID 29226465, PMID 29268891, PMID 29632238, PMID 29878086, PMID 29897428, PMID 29957595, PMID 30127037, PMID 30165617, PMID 30328257, PMID 30957581, PMID 31081342, PMID 31119693, PMID 31129911, PMID 31242362, PMID 31475799, PMID 32310133, PMID 32687741, PMID 32855116, PMID 33032712, PMID 33069847, PMID 33115278, PMID 33139388, PMID 33213722, PMID 33213734, PMID 33714389, PMID 33813727, PMID 34126130
2014 (1), K23HL077597 (1), R01MD019189 (1)